Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting ...Middle East

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN...

Read More Details
Finally We wish PressBee provided you with enough information of ( Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting )

Also on site :

• '70s Star Says 'Star Trek' Actor Is Her 'Favorite Person to Kiss' Besides Her Husband
• Tech Billionaire Reveals Plans To Leave Fortune To All 106 Of His Children
• The Secret Ingredient for The Best-Ever Burger